InvAscent
Healthcare
Why Indian bulk-drug makers are attracting greater investor interest
Private equity investors as well as pharmaceutical companies are showing higher interest in the bulk-drugs segment in India, industry...
Healthcare
Healthcare PE firm InvAscent bets on woman and child care hospital
Healthcare private equity firm InvAscent has stepped into a new single-speciality segment with a fourth deal from its latest fund...
Healthcare
KIMS Hospitals in advanced stage to buy PE-backed regional hospital chain
Krishna Institute of Medical Sciences (KIMS Hospitals), which struck a deal with General Atlantic after withdrawing its initial...
Healthcare
InvAscent's third fund strikes two more deals; hits final close
Healthcare private equity firm InvAscent has struck two new deals from its third fund that just marked its final close, ......
Healthcare
Entrust Family Office invests in skincare clinic chain Oliva
Bengaluru-based Entrust Family Office Investment Advisors, an advisory firm that offers investment services to high-net-worth...
Healthcare
Motilal Oswal PE-InvAscent consortium buys out Actis from Symbiotec
A consortium of mid-market private equity firms InvAscent and Motilal Oswal PE has bought British PE firm Actis' entire stake...
Healthcare
InvAscent topping up oversubscribed healthcare PE fund
Healthcare private equity firm InvAscent is set to add more money to its India-focused third fund before hitting the final ......
Healthcare
Tata Capital targets bigger corpus for second healthcare private equity fund
Tata Capital Ltd has formally kicked off a process to mobilise capital for its second healthcare private equity fund, targeting...
Healthcare
Mid-market PE consortium in talks to buy Actis' stake in Symbiotec
Actis Advisers Pvt. Ltd is in the final stages of negotiations with a consortium of fellow private equity firms to ......
Healthcare
Evolvence India Life Sciences Fund fully exits Chennai drugmaker
Evolvence India Life Sciences Fund, the debut healthcare fund managed by private equity firm InvAscent, has fully exited its nine-year-old...